ХЕЛАЙЛОВИК Энсар (US),КАПОНИГРО Джордано (US),ХОРН-СПЕРОН Томас (US),ЛЕХАР Джозеф (US)
申请号：
RU2018110770
公开号：
RU2018110770A
申请日:
2016.08.24
申请国别(地区):
RU
年份:
2019
代理人:
摘要：
The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer； methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination； pharmaceutical compositions comprising such combination and commercial packages thereto.
